4-[(Z)-3-(dimethylamino)-2-fluoroprop-2-enoyl]-N,N,5-trimethyltriazole-2-carboximidamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(Z)-3-(dimethylamino)-2-fluoroprop-2-enoyl]-N,N,5-trimethyltriazole-2-carboximidamide
• 化学式: C₁₁H₁₇FN₆O
• 分子量: 268.29
• InChiKey: FAFQNRUQCKDOSY-BODUBVDWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2013156780A1

  公开（公告）日：2013-10-24

  The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from –SO2NH2, -SO2NHMe or –SO2NMe2, -SO2NHEt, or -SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated.

  本发明涉及公式（I）的化合物：其中R1为NH2或NHMe；R2为卤素；而R3或R4中的一个为氢，另一个选自-SO2NH2，-SO2NHMe或-SO2NMe2，-SO2NHEt或-SO2NEt2；或其药学上可接受的盐或溶剂。公式（I）的化合物是蛋白激酶抑制剂，特别是环依赖性激酶（CDKs），如CDK9。本发明还涉及制备这些化合物的过程，包括它们的制药组合物以及它们在治疗增殖性疾病，如癌症，以及其他涉及蛋白激酶/CDK活性的疾病或病情中的应用。
• THERAPEUTIC COMPOUNDS
  申请人：Changzhou Le Sun Pharmaceuticals Limited

  公开号：EP2844657A1

  公开（公告）日：2015-03-11